Amyloidosis News - May 2021

The T60A variant of hATTR presents with a high prevalence of neurologic manifestations that are more frequent at an earlier stage than cardiac manifestations. Read More ›

AG10 has the potential to be clinically efficacious in patients with a variety of genotypes associated with both TTR cardiomyopathy and polyneuropathy. Read More ›

Researchers are developing an algorithm to interpret and manage abnormal monoclonal protein studies in the context of presumed ATTR. Read More ›

For the patients interviewed, the impacts of hereditary transthyretin amyloidosis were profound. Read More ›

Investigations of subclinical features in hATTR are warranted to understand the potential role of early disease-modifying treatment. Read More ›

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: